Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 611-631-1 | CAS number: 58190-57-1
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Key study: read-across from analogue substance Wasox-VMAC2
A Local Lymph Node Assay was performed on analogue substance Wasox-VMAC2 in accordance with OECD Guideline 429 (GLP study). The test was performed in groups of five female CBA mice at 0 (control), 100, 50 and 25% of test material and during three consecutive days (total volume of 25 µl per ear). The test item was regarded as a not sensitising, since the SIs of all examined test concentrations were clearly smaller than 3. Based on this result, the read-across approach was applied and the EAC3 substance was determined to be not sensitising under test conditions.
Key study: read-across from analogue substance Wasox-MMAC2
A Local Lymph Node Assay was performed on analogue substance Wasox-MMAC2 in accordance with OECD Guideline 429 (GLP study). The test was performed in groups of five female CBA mice at 0 (control), 100, 50 and 25% of test material and during three consecutive days (total volume of 25 µl per ear). The test item was regarded as a not sensitising, since the SIs of all examined test concentrations were clearly smaller than 3. Based on this result, the read-across approach was applied and the EAC3 substance was determined to be not sensitising under test conditions.
Migrated from Short description of key information:
Key study: Based on read-across approach from experimental data on analogue Wasox-VMAC2 (OECD Guideline 429, GLP study), the test item EAC3 was determined to be not sensitising.
Key study: Based on read-across approach from experimental data on analogue Wasox-MMAC2 (OECD Guideline 429, GLP study), the test item EAC3 was determined to be not sensitising.
Justification for selection of skin sensitisation endpoint:
No study was selected, since all available results were negative.
Justification for classification or non-classification
Based on the available information, the test substance EAC3 is not classified as skin sensitizer according to CLP Regulation (EC) No 1272/2008 since the stimulation indexes obtained in Local Lymph Node Assay were < 3.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
